BioWave

Executive Summary

BioWave is a privately held medical device company headquartered in Port Washington, US, specializing in non-invasive neuromodulation devices for drug-free pain management. Founded in 2003, the company's FDA-cleared portable systems are designed to block pain signals at the nerve source, reducing pain and reliance on medications. BioWave's solutions are utilized within the Veterans Administration and selected clinical pathways, positioning it in the growing opioid-alternative pain management market. The company targets both clinical and home-use settings, offering a versatile approach to chronic and acute pain. BioWave differentiates itself through its non-invasive, drug-free modality with established FDA clearance and VA adoption. While the company operates in a competitive neuromodulation landscape (including players like NeuroMetrix and electroCore), its focus on portable, prescription-based systems and institutional partnerships provides a niche. Growth drivers include expanding VA and DoD contracts, new clinical evidence, and broader payer coverage. However, limited public information hampers comprehensive assessment. Conviction score 58 reflects moderate confidence given niche market and validated technology but constrained visibility.

Upcoming Catalysts (preview)

• Q3 2026Expansion of VA Contract or New DoD Deployment70% success
• Q4 2026Publication of Pivotal Clinical Trial Results60% success
• Q1 2027Strategic Partnership with Major Health System50% success